Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Expanding US operations to address the increased demand for API development and manufacturing
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
New study presents a human-relevant stress model for assessing potential therapeutics
Subscribe To Our Newsletter & Stay Updated
